BackAurobindo Pharma gets USFDA nod for injection to treat osteoporosis
The medicine is a generic version of Swiss pharmaceutical company Novartis AG's Zometa injection
PremiumPhoto: Bloomberg
Hyderabad: Aurobindo Pharma Ltd became the latest Indian generic maker to get US Food and Drug Administration (USFDA) approval to launch zoledronic acid injection of 4 mg/5ml strength.
The medicine, used to treat osteoporosis in women after menopause, is a generic version of Swiss pharmaceutical company Novartis AG’s Zometa (zoledronic acid) injection.
Aurobindo’s zoledronic acid injection is available in a single-use vial for intravenous infusion.
Aurobindo faces stiff competition from at least a dozen companies in the generic space including Indian rivals such as Dr. Reddy’s Laboratories Ltd, Sun Pharma Ltd, Emcure Pharmaceuticals Ltd and Gland Pharma Ltd.
Dr.Reddy’s, which had the largest market share for some time for the zoledronic injection due to low competition, has been losing ground with the entry of other generic drug makers.
The market for zoledronic is said to be around $150-200 million.
Shares of Aurobindo gained 1.81% and were trading at ₹ 874 on the BSE at 11.15am, while the benchmark Sensex dropped 0.05% to 28,239.89 points.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
